Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Equity Average (2016 - 2025)

Karyopharm Therapeutics' Equity Average history spans 13 years, with the latest figure at -$281.1 million for Q4 2025.

  • For Q4 2025, Equity Average fell 62.64% year-over-year to -$281.1 million; the TTM value through Dec 2025 reached -$281.1 million, down 62.64%, while the annual FY2025 figure was -$239.5 million, 48.64% down from the prior year.
  • Equity Average reached -$281.1 million in Q4 2025 per KPTI's latest filing, down from -$254.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $5.5 million in Q1 2021 to a low of -$281.1 million in Q4 2025.
  • Average Equity Average over 5 years is -$126.0 million, with a median of -$111.4 million recorded in 2021.
  • Peak YoY movement for Equity Average: plummeted 1592.32% in 2022, then soared 62.01% in 2023.
  • A 5-year view of Equity Average shows it stood at -$102.8 million in 2021, then rose by 23.69% to -$78.5 million in 2022, then tumbled by 50.76% to -$118.3 million in 2023, then plummeted by 46.1% to -$172.8 million in 2024, then tumbled by 62.64% to -$281.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Equity Average are -$281.1 million (Q4 2025), -$254.1 million (Q3 2025), and -$222.4 million (Q2 2025).